222 related articles for article (PubMed ID: 22297444)
1. Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy.
Tomasello G; Sciumé C; Rappa F; Rodolico V; Zerilli M; Martorana A; Cicero G; De Luca R; Damiani P; Accardo FM; Romeo M; Farina F; Bonaventura G; Modica G; Zummo G; Conway de Macario E; Macario AJ; Cappello F
Eur J Histochem; 2011 Oct; 55(4):e38. PubMed ID: 22297444
[TBL] [Abstract][Full Text] [Related]
2. Colonic mucosal expression of heat-shock proteins may have a potential prognostic value in ulcerative colitis.
Abou El Azm AR; Yousef M; Kobtan A; Awad A; Elkassas G; Elfert A
Arab J Gastroenterol; 2015 Mar; 16(1):20-4. PubMed ID: 25797489
[TBL] [Abstract][Full Text] [Related]
3. The Functions and Therapeutic Potential of Heat Shock Proteins in Inflammatory Bowel Disease-An Update.
Hoter A; Naim HY
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717769
[TBL] [Abstract][Full Text] [Related]
4. Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis.
Tomasello G; Rodolico V; Zerilli M; Martorana A; Bucchieri F; Pitruzzella A; Marino Gammazza A; David S; Rappa F; Zummo G; Damiani P; Accomando S; Rizzo M; de Macario EC; Macario AJ; Cappello F
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):552-61. PubMed ID: 21441812
[TBL] [Abstract][Full Text] [Related]
5. Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham M; Moss AC
Expert Rev Clin Pharmacol; 2012 Mar; 5(2):113-23. PubMed ID: 22390554
[TBL] [Abstract][Full Text] [Related]
6. Quantitative patterns of Hsps in tubular adenoma compared with normal and tumor tissues reveal the value of Hsp10 and Hsp60 in early diagnosis of large bowel cancer.
Rappa F; Pitruzzella A; Marino Gammazza A; Barone R; Mocciaro E; Tomasello G; Carini F; Farina F; Zummo G; Conway de Macario E; Macario AJ; Cappello F
Cell Stress Chaperones; 2016 Sep; 21(5):927-33. PubMed ID: 27491302
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.
Bantel H; Berg C; Vieth M; Stolte M; Kruis W; Schulze-Osthoff K
Am J Gastroenterol; 2000 Dec; 95(12):3452-7. PubMed ID: 11151876
[TBL] [Abstract][Full Text] [Related]
8. Regulatory mechanism of mesalazine on TLR4/MyD88-dependent pathway in mouse ulcerative colitis model.
Li Y; Liu Q; Tang JH; Wen JJ; Zhu JQ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6637-6644. PubMed ID: 31378906
[TBL] [Abstract][Full Text] [Related]
9. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study.
Assisi RF;
Minerva Gastroenterol Dietol; 2008 Sep; 54(3):231-8. PubMed ID: 18614971
[TBL] [Abstract][Full Text] [Related]
10. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment.
Lee HJ; Choi SC; Lee MH; Oh HM; Choi EY; Choi EJ; Yun KJ; Seo GS; Kim SW; Lee JG; Han WC; Park KI; Jun CD
Inflamm Bowel Dis; 2005 Dec; 11(12):1070-9. PubMed ID: 16306769
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of Hsp10 and Hsp90 expression in healthy mucosa and adenocarcinoma of the large bowel.
Rappa F; Sciume C; Lo Bello M; Bavisotto CC; Marino Gammazza A; Barone R; Campanella C; David S; Carini F; Zarcone F; Rizzuto S; Lena A; Tomasello G; Uzzo ML; Spatola GF; Bonaventura G; Leone A; Gerbino A; Cappello F; Bucchieri F; Zummo G; Farina F
Anticancer Res; 2014 Aug; 34(8):4153-9. PubMed ID: 25075042
[TBL] [Abstract][Full Text] [Related]
14. The PDB and protein homeostasis: From chaperones to degradation and disaggregase machines.
Saibil HR
J Biol Chem; 2021; 296():100744. PubMed ID: 33957121
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial heat shock protein (Hsp) 70 and Hsp10 cooperate in the formation of Hsp60 complexes.
Böttinger L; Oeljeklaus S; Guiard B; Rospert S; Warscheid B; Becker T
J Biol Chem; 2015 May; 290(18):11611-22. PubMed ID: 25792736
[TBL] [Abstract][Full Text] [Related]
16. Old but Fancy: Curcumin in Ulcerative Colitis-Current Overview.
Pituch-Zdanowska A; Dembiński Ł; Banaszkiewicz A
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558408
[TBL] [Abstract][Full Text] [Related]
17. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Yamamoto T; Shimoyama T; Matsumoto K
Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
19. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
20. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine.
Haralambou G; Teirstein AS; Gil J; Present DH
Mt Sinai J Med; 2001 Nov; 68(6):384-8. PubMed ID: 11687866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
